Kidney function can improve in patients with hypertensive CKD

Journal of the American Society of Nephrology

Volumn 23, Issue 4, 2012, Pages 706-713

  Hu, Bo ^a   Gadegbeku, Crystal ^b   Lipkowitz, Michael S ^c   Rostand, Stephen ^d   Lewis, Julia ^e   Wright, Jackson T ^f   Appel, Lawrence J ^g   Greene, Tom ^h   Gassman, Jennifer ^a   Astor, Brad C ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IOTALAMIC ACID I 125;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA;

EID: 84859808611     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011050456     Document Type: Article

References (25)

1. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919, 1997 (Pubitemid 27252762)
2. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patientlevel meta-analysis. Ann Intern Med 139: 244-252, 2003
3. Ruggenenti P, Perna A, Remuzzi G Gruppo Italiano di Studi Epidemiologici in Nefrologia: ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12: 2832-2837, 2001 (Pubitemid 33115432)
4. Hsu CY, Lin F, Vittinghoff E, Shlipak MG: Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 14: 2902-2907, 2003 (Pubitemid 37305653)
5. McClellan W, Warnock DG, McClure L, Campbell RC, Newsome BB, Howard V, Cushman M, Howard G: Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol 17: 1710-1715, 2006 (Pubitemid 43794674)
6. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A populationbased study of potential explanatory factors. J AmSoc Nephrol 13: 2363-2370, 2002 (Pubitemid 34925247)
7. Eriksen BO, Ingebretsen OC: The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int 69: 375-382, 2006 (Pubitemid 43323090)
8. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998 (Pubitemid 28304880)
9. Fogo AB: Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804-819, 2001
10. Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, Lash J, Cornish-Zirker D, Peterson G, Toto R, Kusek J, Appel L, Kendrick C, Gassman J; AASK group: Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 50: 78-89, e1, 2007
11. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002 (Pubitemid 35340538)
12. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ,Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl JMed 363: 918-929, 2010
13. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001 (Pubitemid 32525368)
14. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
15. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ameta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001 (Pubitemid 32661190)
16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 345: 861-869, 2001
17. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10: 997-1006, 1999 (Pubitemid 29203086)
18. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 14[Suppl 2]: S148-S153, 2003 (Pubitemid 36750511)
19. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314, 2005 (Pubitemid 46187550)
20. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severemodel of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13: 2898-2908, 2002 (Pubitemid 35386909)
21. Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int 61: 2066-2077, 2002 (Pubitemid 34539324)
22. Appel LJ,Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT: The rationale and design of the AASK cohort study. J Am Soc Nephrol 14[Suppl 2]: S166-S172, 2003 (Pubitemid 36750513)
23. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR: Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 14[Suppl 2]: S154-S165, 2003 (Pubitemid 36750512)
24. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J Jr African-American Study of Hypertension and Kidney Disease: Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 38: 744-753, 2001
25. Pinheiro J, Bates D: Mixed-Effects Models in S and S-PLUS, New York, Springer Verlag, 2000